2026 Interim report
Filed with HKEX · Stock code 2659 · · 81 pages · English
Summary by 6ix AI
Additionally, it discusses collaborations with other pharmaceutical companies to enhance product development and market access strategies. The report also includes corporate governance information and the composition of the board of directors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shanghai Bao Pharmaceuticals Co Ltd on 6ix
Earlier from Shanghai Bao Pharmaceuticals
Later from Shanghai Bao Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - ind for BJ045 for injection was approved by nmpa
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Shanghai Bao Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Bao Pharmaceuticals